JW Pharmaceutical has launched an initiative to educate healthcare professionals about the clinical applications of Winuf Inj., their omega-3-based comprehensive nutritional infusion, while promoting evidence-based infusion therapy.
The company announced on Friday that it presented on the clinical benefits of Winuf Inj. at a recent academic conference held by the Seoul Internal Medicine Association at the Lotte Hotel in Seoul.
Dr. Moon Eun-seon from Olive Internal Medicine Clinic led the presentation, focusing on infusion therapy for acute gastroenteritis patients and the anti-inflammatory properties of omega-3-rich nutritional infusions. Dr. Moon stressed the importance of treatment approaches that prioritize healing damaged intestinal tissue and reducing inflammation, rather than merely alleviating symptoms such as diarrhea, abdominal pain, and high fever in patients with inflammatory bowel conditions.
The presentation also highlighted how infusion therapy using 217mL of Winuf Inj. could aid in repairing the damaged intestinal barrier and managing inflammation. Additionally, Dr. Moon introduced strategies to minimize the risk of intestinal mucosal damage often associated with conventional antipyretic and anti-inflammatory analgesics.
Winuf Inj., developed and manufactured by JW Life Science and marketed domestically by JW Pharmaceutical, is an innovative comprehensive nutritional infusion. It employs a unique Three-Chamber design, separating amino acids, glucose, and lipids for storage, which are mixed just before administration. The product is distinguished by its optimized ratio of omega-3 to omega-6 fatty acids.
Building on the clinical evidence supporting Winuf Inj., JW Pharmaceutical aims to expand its academic outreach to healthcare professionals and continue enhancing the dissemination of medical information related to infusion and nutritional therapy.
A company spokesperson stated that this presentation was organized to share treatment strategies that address both dehydration and nutritional depletion in acute gastroenteritis patients. It’s committed to providing innovative infusion therapy solutions based on robust clinical evidence.
